Oncology On GDF-15 neutralisation and cachexia, with CatalYm As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.
News ESMO26: Evidence for GSK's mo-rez builds in ovarian cancer New data from GSK's BEHOLD-1 study of B7-H4-targeted ADC mo-rez reinforces earlier results in platinum-resistant ovarian cancer.
News ESMO26: Halda buy delivers a win for J&J in prostate cancer A drug at the heart of Johnson & Johnson's $3bn takeover of Halda has been shown to be "highly active" in a first-in-human prostate cancer trial.
News ESMO26: BMS dual-acting ADC beats chemo in breast cancer BMS and SystImmune's EGFRxHER3 bispecific ADC iza-bren has scored in another phase 3 trial, boosting its credentials as a future blockbuster.
News ESMO26: Zai and Ideaya showcase DLL3 drugs in lung cancer Two drugs hoping to muscle in on Amgen's first-to-market DLL3-targeting drug Imdelltra – from Zai Lab and Ideaya – have new trial readouts at ESMO.
News ESMO26: Neoadjuvant Enhertu fails in early breast cancer AstraZeneca and Daiichi Sankyo's Enhertu failed to show efficacy as neoadjuvant therapy for early-stage HER2-low breast cancer in the TALENT trial.
News BMS shakes up R&D under CMO Cristian Massacesi Bristol Myers Squibb is combining its R&D operations into a single unit led by chief medical officer and development head Cristian Massacesi.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.
